Logo Image
News|Articles|June 2, 2026

PolyPid Completes FDA NDA Submission for D-PLEX100 in Surgical Site Infection Prevention

PolyPid has completed its New Drug Application submission to the FDA for D-PLEX100, a novel locally administered antibiotic therapy that significantly reduced surgical site infections in a phase 3 trial and could receive a regulatory decision in early 2027.

PolyPid announced the completion of its rolling New Drug Application (NDA) submission to the FDA for D-PLEX100, its lead investigational therapy designed to prevent surgical site infections (SSIs) in patients undergoing colorectal surgery. If approved, the product would address a major unmet need in surgical care, where SSIs remain a significant cause of postoperative complications, hospital readmissions, and healthcare costs.

The NDA is supported by findings from the phase 3 SHIELD II trial, which met its primary endpoint and all key secondary endpoints. The study demonstrated a 60% relative reduction in surgical site infections compared with standard of care (p=0.0013). D-PLEX100 has also received FDA Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product (QIDP) designations, positioning it for potential Priority Review.

What You Need to Know

PolyPid has completed its NDA submission to the FDA for D-PLEX100, advancing the therapy toward a potential approval decision in the first quarter of 2027.

In the pivotal SHIELD II trial, D-PLEX100 reduced the risk of surgical site infections by 60% compared with standard care while meeting all primary and key secondary endpoints.

The therapy's localized, sustained-release doxycycline delivery system is designed to provide targeted infection prevention at the surgical site for up to 30 days with limited systemic exposure.

“Completing the NDA submission for D-PLEX100 is a defining milestone for PolyPid and the culmination of years of disciplined clinical and regulatory work,” PolyPid CEO Dikla Czaczkes Akselbrad, said in a statement. “With the full application now before the FDA, we are focused on supporting the agency’s review, finalizing our US commercial partnership discussions, and preparing for the potential approval and launch of a novel approach to the prevention of SSIs.”

D-PLEX100 utilizes PolyPid’s proprietary Kynatrix technology to deliver doxycycline directly at the surgical site during wound closure, providing controlled antibiotic release for approximately 30 days while minimizing systemic exposure. The FDA's target action date under the Prescription Drug User Fee Act (PDUFA) is currently anticipated in the first quarter of 2027.


Reference
1.PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀. Global Newswire. June 1, 2026. Accessed June 2, 2026.
https://www.globenewswire.com/news-release/2026/06/01/3304355/0/en/PolyPid-Completes-New-Drug-Application-Submission-to-FDA-for-D-PLEX.html

Related to this article

View more
Measles Update: October 2, 2026
Measles Update: October 2, 2026
The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
Read more
Measles Update: September 25, 2026
Measles Update: September 25, 2026
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
Read more
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.
Read more